The global coronary artery disease (CAD) market will reach $38.17B in 2028 from $22.94B in 2022, growing at a CAGR of 8.86%, according to a report by Research & Markets.
The increasing prevalence of CAD due to aging populations, unhealthy lifestyles, and rising rates of obesity and diabetes is driving growth in the coronary artery disease market. Furthermore, advances in medical technology and research have also led to new and more effective therapies for CAD, including drug-eluting stents and minimally invasive procedures. In addition, tailoring treatment plans to individual patients based on their unique factors is becoming increasingly popular, known as personalized medicine.
Antiplatelet drugs are the dominant therapy in the coronary artery disease market, as they are widely used to prevent blood clots that can lead to heart attacks and strokes in patients with CAD. In addition, they have been proven effective in reducing the risk of recurrent cardiovascular events and have a low risk of side effects, making them a safe long-term option for CAD patients.